TICKERNOMICS Sign up
Last Update: 2023-12-23 05:59:10
Ultragenyx Pharmaceutical Inc. ( RARE ) https://www.ultragenyx.com
45.54USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
RARE
4.64%
SPY
30.72%
-74.33%
RARE
SPY
112.82%
RARE
16.14%
SPY
201.04%
RARE
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
3263.60
2925.49
0.58
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.14
7.96
102.91
-15.74
0.00
-5.13
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-147.98
88.79
-139.11
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.8408
-73.30
-45.12
0.72
Other Earnings and Cash Flow Stats:
Ultragenyx Pharmaceutical Inc. ( RARE ) Net Income TTM ($MM) is -720.56
Ultragenyx Pharmaceutical Inc. ( RARE ) Operating Income TTM ($MM) is -669.90
Ultragenyx Pharmaceutical Inc. ( RARE ) Owners' Earnings Annual ($MM) is 0.00
Ultragenyx Pharmaceutical Inc. ( RARE ) Current Price to Owners' Earnings ratio is 0.00
Ultragenyx Pharmaceutical Inc. ( RARE ) EBITDA TTM ($MM) is -650.72
Ultragenyx Pharmaceutical Inc. ( RARE ) EBITDA Margin is -139.11%
Capital Allocation:
Ultragenyx Pharmaceutical Inc. ( RARE ) has paid 0.00 dividends per share and bought back -1.61032 million shares in the past 12 months
Ultragenyx Pharmaceutical Inc. ( RARE ) has reduced its debt by 9.582 million USD in the last 12 months
Capital Structure:
Ultragenyx Pharmaceutical Inc. ( RARE ) Interest-bearing Debt ($MM) as of last quarter is 31
Ultragenyx Pharmaceutical Inc. ( RARE ) Annual Working Capital Investments ($MM) are -142
Ultragenyx Pharmaceutical Inc. ( RARE ) Book Value ($MM) as of last quarter is 31
Ultragenyx Pharmaceutical Inc. ( RARE ) Debt/Capital as of last quarter is 8%
Other Balance Sheet Stats:
Ultragenyx Pharmaceutical Inc. ( RARE ) has 72 million in cash on hand as of last quarter
Ultragenyx Pharmaceutical Inc. ( RARE ) has 253 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Ultragenyx Pharmaceutical Inc. ( RARE ) has 71 common shares outstanding as of last quarter
Ultragenyx Pharmaceutical Inc. ( RARE ) has 0 million USD of preferred stock value
Academic Scores:
Ultragenyx Pharmaceutical Inc. ( RARE ) Altman Z-Score is -3.05 as of last quarter
Ultragenyx Pharmaceutical Inc. ( RARE ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Ultragenyx Pharmaceutical Inc. ( RARE ) largest shareholder is AllianceBernstein L.P. owning 1532505 shares at 69.79 ($MM) value
Thomas Richard Kassberg(an insider) Sold 39878 shares of Ultragenyx Pharmaceutical Inc. ( RARE ) for the amount of $1307200.84 on 2023-10-23
4.67% of Ultragenyx Pharmaceutical Inc. ( RARE ) is held by insiders, and 98.58% is held by institutions
Ultragenyx Pharmaceutical Inc. ( RARE ) went public on 2014-01-31
Other Ultragenyx Pharmaceutical Inc. ( RARE ) financial metrics:
FCF:-402.16
Unlevered Free Cash Flow:0.00
EPS:-8.91
Operating Margin:-147.98
Gross Profit Margin:88.79
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-2013.61
Beta:0.72
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Ultragenyx Pharmaceutical Inc. ( RARE ) :
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.